The Top Drug Product Classes Advertising in Professional Health Journals through Q1 2014

by Client Services

Print advertising dollars in professional health journals reached more than $146 million through March 2014, a 3% increase year-over-year, according to Kantar Media. Cancer Therapy Products continue to lead the product classes with nearly $10 million spent in advertising.  It makes up about 7% of the total market through Q1. As a whole, oral diabetes drugs invested almost $6 million in advertising in medical journals through the first three months of the year.

The top product classes by dollars are as follows:

Top 5 Print Ad Drug Classes (Dollars): March 2014

#1 Cancer Therapy Products - $10 MM (-12%)

#2 Diabetes Oral - $6 MM (+374%)

#3 Anticoagulants Oral - $5 MM (-36%)

#4 SSRI/SNRI - $4 MM (+361%)

#5 Antidepressants - $3 MM (N/A)

The percentage changes compare March 2014 to that same time period in 2013. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.